Boglarka Gyurkocza, M.D.

boglarka gyukorcza

Fred Hutchinson Cancer Research Center
Reducing Relapse of Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

We are conducting two clinical trials with novel, minimally toxic conditioning regimens – combining treosulfan or clofarabine, instead of fludarabine, with hematopoietic cell transplantation (HCT). Our goal is to reduce the incidence of recurrent leukemia following HCT, thereby increasing the likelihood of long-term survival.